Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)-Like Pigmentation in a Metastatic Breast Cancer Patient.
Ashy dermatosis
Breast
Erythema dyschromicum perstans
Ribociclib
Journal
Journal of breast cancer
ISSN: 1738-6756
Titre abrégé: J Breast Cancer
Pays: Korea (South)
ID NLM: 101314183
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
27
05
2020
revised:
23
07
2020
accepted:
27
08
2020
entrez:
26
2
2021
pubmed:
27
2
2021
medline:
27
2
2021
Statut:
ppublish
Résumé
Ribociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor that has been approved in combination with endocrine therapy for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative advanced or metastatic breast cancer. The main dermatological adverse events associated with CDK 4/6 inhibitors that are described in the literature include skin rash, an increased risk of alopecia, and stomatitis. Erythema dyschromicum perstans (EDP), also known as ashy dermatosis, is characterized by acquired small and large slate-gray hyperpigmented macules with erythematous borders. There are currently no published reports of EDP-like or pigmentary changes induced by CDK 4/6 inhibitors. This report describes the first case of EDP-like pigmentation associated with ribociclib therapy.
Identifiants
pubmed: 33634626
pii: 24.117
doi: 10.4048/jbc.2021.24.e1
pmc: PMC7920864
doi:
Types de publication
Case Reports
Langues
eng
Pagination
117-121Informations de copyright
© 2021 Korean Breast Cancer Society.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Expert Rev Anticancer Ther. 2017 Sep;17(9):851-856
pubmed: 28699811
Clin Breast Cancer. 2018 Oct;18(5):e755-e758
pubmed: 30120047
Rep Pract Oncol Radiother. 2019 May-Jun;24(3):276-280
pubmed: 30948930
Australas J Dermatol. 2019 Aug;60(3):e232-e233
pubmed: 30565221
J Cutan Med Surg. 2018 May/Jun;22(3):341-343
pubmed: 29307217
J Breast Cancer. 2019 Sep 18;22(4):661-666
pubmed: 31897340
JAAD Case Rep. 2020 Jan 17;6(2):86-88
pubmed: 32051836
Oncologist. 2017 Sep;22(9):1039-1048
pubmed: 28706010
Int J Dermatol. 2019 Mar;58(3):263-272
pubmed: 30176055
Clin Cancer Res. 2018 Jul 1;24(13):2999-3004
pubmed: 29437768